lmfin 90 - tittels., forord, innledn - Nasjonalt folkehelseinstitutt

fikk sulfonamider. Bruken av tiazolidindioner
(”glitazoner”, A10BG) er relativt sett lav, men
salget av faste kombinasjoner som inneholder
glitazoner øker kraftig.
To legemidler som påvirker inkretinsystemet
ble markedsført i 2007: Januvia® (A10BH01)
og Byetta® (A10BX04). Preparatene
representerer nye virkningsmekanismer og er
foreløpig indisert kun som tilleggsbehandling
ved type 2-diabetes.
29
ATC gruppe A
The sales measured in DDDs of oral agents
for the treatment of Type 2 diabetes
increased by 7 % in 2007. Metformin
(A10BA02) and glimepiride (A10BB12)
accounted for 47 % and 41 % respectively of
the total sales of oral antidiabetics in 2007.
Data from the NorPD show that 80 000
patients received metformin and 45 000
received sulfonamides. The use of
thiazolidinediones (“glitazones”, A10BG) is
relatively speaking low in this group, however,
the sales of combination products containing
glitazones is increasing significantly.
Two medicinal products with effect on the
incretin system were introduced on the
market in 2007: Januvia® (A10BH01) and
Byetta®). These products represent new
mechanisms of action and so far they are
indicated only as adjunctive therapy in the
treatment of patients with Type 2 diabetes.